CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


We found 7176 result(s)

Testing of Mitochondrial DNA and Mitochondrial Respiratory Chain Complexes

Last Updated: December 1, 2014
Result type: Reports
Product Line: INESSS

These tests are indicated for patients who have been diagnosed clinically with a mitochondrial disorder, and cases where a mitochondrial disorder is strongly suspected. Analysis of respiratory chain complexes and mitochondrial DNA (mtDNA) is used to confirm the clinical diagnosis of a particular syndrome and to diagnose following the manifestati...

Culturing Change in Lab Testing: Webinar

Event Date: December 1, 2014
Result type: Events

This engaging webinar will kick off a series of cross-Canada events focused on using lab tests appropriately. With a significant number of medical decisions being influenced by lab test results, governments, health care administrators, and clinical and lab associations are turning their focus to ensuring lab tests are used appropriately. When l...

Zilver PTX Drug-Eluting Peripheral Stents to Treat Peripheral Arterial Disease of the Femoropopliteal Vessels

Last Updated: November 28, 2014
Result type: Reports

The Zilver PTX drug-eluting peripheral stent is a minimally invasive endovascular drug/device combination used to treat the de novo or restenotic, symptomatic lesions of peripheral arterial disease in the (above-the-knee) superficial femoral and popliteal arteries. There appears to be promising evidence from randomized trials and oth...

  • Project Number: EH0017-000

Alemtuzumab (Lemtrada)

Last Updated: November 27, 2014
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Alemtuzumab
Indications: Multiple Sclerosis, relapsing-remitting

  • Brand Name: Lemtrada
  • Manufacturer: Genzyme Canada, a Division of Sanofi-Aventis Canada Inc.
  • Project Number: SR0405-000
  • Project Status: Complete
  • Submission Type: Initial

Emerging Oral, Combination, Interferon-Free Regimens for the Treatment of Chronic Hepatitis C Genotype 1

Last Updated: November 20, 2014
Result type: Reports

All-oral, interferon-free regimens for the treatment of chronic hepatitis C genotype 1 are alternatives to the combination of direct-acting antivirals with pegylated interferon and ribavirin. These regimens include multiple direct-acting antiviral agents with different mechanisms of action. Of the regimens, only the combinations of ledipasvir...

  • Project Number: EH0015-000